Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of nivobotulinumtoxinA for glabellar lines
2018-004384-31Phase 3Completed
- Sponsor
- Allergan
- Start
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in glabellar furrowing comparing nivobotulinumtoxinA with placebo (2 arms). Primary endpoint: Composite responder rate at Day 30. Started Jun 2019; status: completed.
02
Drugs
nivobotulinumtoxinA
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on 2018-004384-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004384-31.